503 related articles for article (PubMed ID: 20557130)
1. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Tsume Y; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Feasibility of Biowaiver Extension of BCS Class III Drugs with Site-Specific Absorption Using Gastrointestinal Simulation Technology.
Sun L; Sun J; He Z
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):471-487. PubMed ID: 27447171
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
5. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system.
Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S
Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662
[TBL] [Abstract][Full Text] [Related]
6. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation.
Kovacević I; Parojcić J; Homsek I; Tubić-Grozdanis M; Langguth P
Mol Pharm; 2009; 6(1):40-7. PubMed ID: 19248231
[TBL] [Abstract][Full Text] [Related]
7. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests.
Kim JS; Mitchell S; Kijek P; Tsume Y; Hilfinger J; Amidon GL
Mol Pharm; 2006; 3(6):686-94. PubMed ID: 17140256
[TBL] [Abstract][Full Text] [Related]
8. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
[TBL] [Abstract][Full Text] [Related]
9. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug.
Colón-Useche S; González-Álvarez I; Mangas-Sanjuan V; González-Álvarez M; Pastoriza P; Molina-Martínez I; Bermejo M; García-Arieta A
Mol Pharm; 2015 Sep; 12(9):3167-74. PubMed ID: 26287948
[TBL] [Abstract][Full Text] [Related]
10. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
11. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
[TBL] [Abstract][Full Text] [Related]
12. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity.
Radwan A; Amidon GL; Langguth P
Biopharm Drug Dispos; 2012 Oct; 33(7):403-16. PubMed ID: 22782559
[TBL] [Abstract][Full Text] [Related]
14. Computer simulations for bioequivalence trials: selection of analyte in BCS drugs with first-pass metabolism and two metabolic pathways.
Navarro-Fontestad C; Gonzalez-Alvarez I; Fernández-Teruel C; Garcia-Arieta A; Bermejo M; Casabó VG
Eur J Pharm Sci; 2010 Dec; 41(5):716-28. PubMed ID: 20932901
[TBL] [Abstract][Full Text] [Related]
15. Biowaiver extension potential and IVIVC for BCS Class II drugs by formulation design: Case study for cyclosporine self-microemulsifying formulation.
Yang SG
Arch Pharm Res; 2010 Nov; 33(11):1835-42. PubMed ID: 21116787
[TBL] [Abstract][Full Text] [Related]
16. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
Lindenberg M; Kopp S; Dressman JB
Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
[TBL] [Abstract][Full Text] [Related]
17. Justification of metformin hydrochloride biowaiver criteria based on bioequivalence study.
Homsek I; Parojcić J; Dacević M; Petrović L; Jovanović D
Arzneimittelforschung; 2010; 60(9):553-9. PubMed ID: 21117498
[TBL] [Abstract][Full Text] [Related]
18. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
19. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
Mishra V; Gupta U; Jain NK
Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
[TBL] [Abstract][Full Text] [Related]
20. Impact of Biopharmaceutics Classification System-based biowaivers.
Cook JA; Davit BM; Polli JE
Mol Pharm; 2010 Oct; 7(5):1539-44. PubMed ID: 20735084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
